Anthracycline glycosides
    8.
    发明授权
    Anthracycline glycosides 失效
    蒽环类苷

    公开(公告)号:US4522815A

    公开(公告)日:1985-06-11

    申请号:US499308

    申请日:1983-05-31

    CPC分类号: C07H15/252 Y02P20/55

    摘要: Disclosed is a process for preparing the glycoside antitumor anthracyclines 7-0-(2,6-dideoxy-.alpha.-L-arabino-hexopyranosyl)-daunomycinone (Ia); 4-demethoxy-7-0-(2,6-dideoxy-.alpha.-L-arabino-hexopyranosyl)-daunomycinone (Ib); 7-0-(2,6-dideoxy-.alpha.-L-arabino-hexopyranosyl)-adriamycinone (Ic); 4-demethoxy-7-0-(2,6-dideoxy-.alpha.-L-arabino-hexopyranosyl)-adriamycinone (Id); 7-0-(2,3,6-trideoxy-.alpha.-L-erythro-hex-2-enopyranosyl)-daunomycinone (IIa); 4-demethoxy-7-0-(2,3,6-trideoxy-.alpha.-L-erythro-hex-2-enopyranosyl)-daunomycinone (IIb); 7-0-(2,3,6-trideoxy-.alpha.-L-erythro-hex-2-enopyranosyl)-adriamycinone (IIc); and 4-demethoxy-7-0-(2,3,6-trideoxy-.alpha.-L-erythro-hex-2-enopyranosyl)-adriamycinone (IId). Compounds Ia, Ib, IIa, IIb are prepared by condensing daunomycinone and 4-demethoxydaunomycinone with 3,4-di-0-acetyl-2,6-dideoxy-.alpha.-L-arabino-hexopyranosyl chloride in an inert solvent in the presence of silver triflate (silver trifluoromethansulfonate), as catalyst, and by removing the protecting groups. Analogously the derivatives Ic, Id, IIc and IId are prepared by condensing a novel reactive protected derivative of adriamycinone and 4-demethoxyadriamycinone in the presence of mercuric bromide/mercuric oxide with the above mentioned sugar halide. The new compounds of the invention are useful in treating certain tumors in mammals.

    摘要翻译: 公开了制备糖苷抗肿瘤蒽环类抗生素7-0-(2,6-二脱氧-α-α-阿拉伯 - 六吡喃糖基) - 日诺霉素酮(Ia)的方法; 4-脱甲氧基-7-0-(2,6-二脱氧-α-α-阿拉伯 - 六吡喃糖基) - 日诺霉素酮(Ib); 7-0-(2,6-二脱氧-α-L-阿拉伯 - 六吡喃糖基) - 阿德米霉素(Ic); 4-脱甲氧基-7-0-(2,6-二脱氧-α-L-阿拉伯 - 六吡喃糖基) - 阿德米霉素(Id); 7-0-(2,3,6-三脱氧-α-L-赤 - 己-2- -2-吡喃糖基) - 日诺霉素酮(IIa); 4-脱甲氧基-7-0-(2,3,6-三脱氧-α-L-赤 - 己-2- -2-吡喃糖基) - 日诺霉素酮(IIb); 7-0-(2,3,6-三脱氧-α-L-赤 - 己-2- -2-吡喃糖基) - 阿德米霉素(IIc); 和4-脱甲氧基-7-0-(2,3,6-三脱氧-α-L-赤 - 二-2-吡喃葡萄糖基) - 阿德米霉素(IId)。 化合物Ia,Ib,IIa,IIb是通过在惰性溶剂中存在下,将道诺霉素酮和4-脱甲氧基多余霉素酮与3,4-二-O-乙酰基-2,6-二脱氧-α-L-阿拉伯 - 六吡喃葡萄酰氯缩合制备的 三氟甲磺酸银(三氟甲磺酸银),作为催化剂,除去保护基。 类似地,衍生物Ic,Id,IIc和IId是通过在溴化汞/氧化汞存在下与上述卤化糖缩合一种新型的反应性保护的阿霉素和4-脱甲氧基对映体霉素衍生物来制备的。 本发明的新化合物可用于治疗哺乳动物中的某些肿瘤。

    2-acyloxy-4-morpholinyl anthracyclines
    9.
    发明授权
    2-acyloxy-4-morpholinyl anthracyclines 失效
    2-酰氧基-4-吗啉基蒽环类

    公开(公告)号:US5510469A

    公开(公告)日:1996-04-23

    申请号:US987281

    申请日:1993-05-12

    CPC分类号: C07H15/252

    摘要: Anthracycline glycosides of formula 1: ##STR1## wherein R.sub.1 is hydrogen or methoxy group; R.sub.2 is hydrogen or hydroxy; both R.sub.3 and R.sub.4 represent hydrogen or one of R.sub.3 and R.sub.4 is hydroxy and the other of R.sub.3 and R.sub.4 a represents hydrogen; R.sub.5 represents hydrogen atom or an acyl residue--COX in which X is a C.sub.1 -C.sub.8 linear or branched alkyl chain, an aryl, an aryl lower alkyl, or a 5- or 6-membered heteroaromatic group are anti-tumour agents.

    摘要翻译: PCT No.PCT / EP91 / 01506 Sec。 371日期:1993年5月12日 102(e)日期1993年5月12日PCT 1991年8月8日PCT PCT。 出版物WO92 / 04362 1992年3月19日。式1的蒽环糖苷:其中R1是氢或甲氧基; R2是氢或羟基; R3和R4分别代表氢或R3和R4之一是羟基,R3和R4中的另一个代表氢; R5表示氢原子或其中X为C1-C8直链或支链烷基链,芳基,芳基低级烷基或5或6元杂芳族基团的酰基残基-COX为抗肿瘤剂。